• Company Information
  • Business Outline
  • Pipeline
  • IR Information
  • Contact
Breakthrough virotherapy for cancer

Oncolys BioPharma continuously evolve its business to develop breakthrough therapy and diagnostics in cancer treatment from early to late stage, including early detection, loco-regional therapy, prognostic test, and systemic treatments.
Our mission is to help both patients and physicians through developing effective and innovating drugs.

Information Past News
May. 26, 2016
News Release
Completion of Highest Single-Dose Level Clinical Trial of OBP-301 (Telomelysin®), Phase I/II in Taiwan and Korea
May. 25, 2016
News Release
OBP-1101(TelomeScan F35) research by Dr. Tanemura awarded in the 70th Meeting of the Japanese Society for Advancement of Surgical Techniques (JSAST)
May. 20, 2016
News Release
Announcement of Letter of Intent for OBP-301(Telomelysin®) license in China
May. 20, 2016
News Release
Announcement of Amended License Agreement for OBP-1101(TelomeScan F35)
May. 6, 2016
News Release
Oncolys BioPharma proudly participates in BIOtech Japan 2016 from 11th to 13th May at Tokyo Big Sight
Apr. 6, 2016
Others
Our business partner,LIQUID BIOTECH USA, INC. announcing a completion of Proof-Of-Concept (POC) clinical study that triggers a $1M milestone payment from Oncolys BioPharma, Inc.
Mar. 19, 2016
News Release
The 88th Annual Meeting of Japanese Gastric Cancer Association - OBP-301 (Telomelysin®) introduced in a luncheon seminar "The trends of new drug development for the treatment of advanced gastric cancer"
Mar. 3, 2016
Publications
The paper relating to TelomeScan® was published on"Molecular Therapy — Methods & Clinical Development"
Feb. 23, 2016
News Release
The 23rd International Annual Molecular Med TRI-CON 2016, San Francisco, CA. - our TelomeScan® research collaborator Dr. Dorsey (Department of Radiation Oncology, University of Pennsylvania) to hold a luncheon seminar on Wed 9 March, to discuss the association of "telomerase-dependent CTC findings" with treatment response in a variety of cancer patient populations.
Feb. 22, 2016
Others
Our business partner,LIQUID BIOTECH USA, INC. was selected as a finalist in the 2016 Enterprise Awards Life Sciences Startup Category by PACT.
pagetop